Contact Us
Back

Marwood Webinar | July 2024 Pre-Recess Legislative & Regulatory Update

Our experts Mark Galay, Stephen Williams, Kim Vukhac, and Joe Mercer discuss recent legislative & regulatory catalysts, including Congressional priorities entering August recess and setting up for the lame-duck session as well as the recently proposed Calendar Year 2025 rules

Key Topics Include:
  • 2025 PFS, OPPS, and Home Health rules
  • Ongoing Congressional and FTC scrutiny of PBMs
  • IRA drug pricing negotiations
  • Medicare Advantage bids, prior authorization, and broker rules
  • SCOTUS overturning Chevron deference
  • Treat and Reduce Obesity Act Committee markup and outlook
  • Radiopharmaceutical Imaging agents reimbursement outlook
Mark Galay
Mark Galay
Vice President | Congressional Health Policy Senior Analyst
Mark Galay

Mr. Galay focuses on legislative affairs, maintaining Congressional and industry relations, and healthcare policy analysis for Marwood Group. Previously, he served as the Legislative Assistant for a senior member of the House Ways & Means Committee. In his work, he developed the Congressman’s legislative health care agenda, introducing several pieces of legislation, some of which signed into law. He advised the Congressmen on key health policy initiatives such as the 21st Century Cures Act, the repeal & replace debate, and the SUPPORT for Patients and Communities Act.  Mr. Galay studied Biology and Chemistry at Cleveland State University.

Stephen Williams, Ph.D.
Stephen Williams, Ph.D.
Director | Pharma/Biotech and Life Sciences Senior Analyst
Stephen Williams, Ph.D.

Dr. Williams leads Marwood’s Products Team, which includes coverage of pharmaceuticals, biotechnology, clinical laboratories, dialysis, PBMs and devices.  This includes focusing on analyzing regulatory issues related to the Food and Drug Administration (FDA) and other federal agencies responsible for regulating medical products. Prior to joining the Marwood Group, Dr. Williams was an investment banker focused on pharmaceutical and biotechnology companies. He was engaged in helping both privately held and publicly traded companies raise growth capital and develop business development strategies. Prior to that, he was an equity analyst covering the pharmaceutical and biotech industries and covered over a dozen U.S. and European companies. Prior to working in the financial sector, Dr. Williams was a biomedical researcher and has held faculty positions at Vanderbilt University and Baylor College of Medicine. He holds a PhD in pharmacology from London University and an MBA from George Washington University.

Kim Vukhac
Kim Vukhac
Director: Pharma/Biotech And Life Sciences
Kim Vukhac

Ms. Vukhac focuses on analyzing issues related to the Food and Drug Administration (FDA) and other agencies responsible for regulating medical products. Prior to joining the Marwood Group, Ms. Vukhac was a senior equity research analyst at CLSA/Credit Agricole Securities (USA) covering the specialty and large-cap pharmaceutical sectors. Prior to that, Ms. Vukhac was healthcare portfolio manager and analyst at Balyasny Asset Management following the specialty and large-cap pharmaceutical sectors and small/mid-cap medical device sector. Prior to her experience in asset management, Ms. Vukhac was an analyst and member of the six-time #1 Institutional Investor ranked team covering specialty pharmaceuticals at Bank of America Securities and Credit Suisse First Boston. Ms. Vukhac holds a Bachelor of Arts in economics from the University of Pennsylvania.

Joe Mercer
Joe Mercer
Managing Director | Managed Care and Healthcare Services Senior Analyst
Joe Mercer

Mr. Mercer leads Marwood’s healthcare services and managed care practices. Prior to joining the Marwood Group, Mr. Mercer served as a Program Analyst at the Center for Consumer Information and Insurance Oversight (CCIIO) division at CMS. From his tenure at CCIIO, Mr. Mercer brings with him substantial expertise covering government health insurance programs with a focus on ACA exchange and Medicare Advantage policy issues and catalysts.  As a Program Analyst at CCIIO, some of Mr. Mercer’s core responsibilities included tracking Federal and State legislative and regulatory changes, translating statutory and regulatory requirements into policy guidance, analyzing provisions of the Affordable Care Act for Federal and State regulators as well as health insurers, serving as a health insurance issuer rating subject matter expert, and collaborating with other CCIIO groups and contractors with a primary focus on working with the Federally Facilitated Marketplace development and policy teams. Mr. Mercer holds a JD from Washington & Lee University School of Law and a BA in Economics from the College of William and Mary.